19 August 2014 USA-based clinical research organisation gives approval to SATVI

8 Jan 2014 - 15:00

Scientists at the UCT based South African Tuberculosis Vaccine Initiative (SATVI) were ecstatic with the announcement by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA that SATVI meets it’s stringent requirements for participation in international clinical trials.

On Tuesday 19 August 2014, the DAIDS Branch Chief, Ms Donna Germuda announced that “SATVI has met all the stringent requirements of the DAIDS site approval process”.

This approval by DAIDS means that SATVI, as part of the UCT Clinical Trials Unit (UCTCTU) headed by Professor Linda-Gail Bekker, will be able to participate in DAIDS-funded clinical research for the development of therapies, interventions and strategies to treat and prevent HIV–related tuberculosis co-infection.

According to Associate Professor Mark Hatherill, SATVI Director, he was very pleased with this important milestone which SATVI has just attained. After a recent visit from DAIDS, he noted “It was very clear that our visitors from DAIDS were highly impressed with the professionalism of each and every SATVI staff member they met during the accreditation process”.

The driving force behind this complex project, Dr Katrina Downing, told us that “this approval is a fantastic accolade for the SATVI team who worked on the seven month long application process and who, despite the enormity of the application process, remained focused, enthusiastic and dedicated. SATVI will now be able to expand into HIV-related clinical trials. According to her, the next exciting step, will be the site activation by the AIDS Clinical Trials Group (ACTG), a clinical trial network of DAIDS.

Mrs Marwou de Kock Field Site Manager, said she was excited about the reward which has come at the end of this long process to get accredited. “I’m so proud to be working with such a wonderful group of people! “